| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 391.92 | 2.4% |
| Total Income | 391.92 | 2.4% |
| Expenditure | 380.45 | 4.5% |
| PBT | -2.41 | 92.0% |
| Net Profit | -4.62 | 81.7% |
| OPM | 2.93% | 6.98pp |
| NPM | -1.18% | 5.43pp |
| EPS | -0.06 | 81.8% |
Integra LifeSciences Reports Q1 2026 Revenue Up 2.4% to $391.9 Million
05 May 2026 · 5 May, 3:51 pm
Summary
Integra LifeSciences reported a 2.4% increase in first quarter revenues, reaching $391.9 million. Organic revenue grew by 1.3%. The company's GAAP earnings per diluted share improved to $(0.06) from $(0.33) in the prior year, while adjusted earnings per diluted share increased to $0.54 from $0.41. Integra reaffirmed its full year revenue guidance and updated its adjusted earnings per share guidance to a range of $2.40 to $2.50.
Key Highlights
- 1
Integra LifeSciences reported first quarter revenues of $391.9 million, an increase of 2.4% on a reported basis compared to the prior year.
- 2
Organic revenue increased by 1.3% compared to the first quarter of 2025.
- 3
GAAP earnings per diluted share was $(0.06), compared to $(0.33) in the prior year.
- 4
Adjusted earnings per diluted share was $0.54, compared to $0.41 in the prior year.
- 5
The company reaffirmed its 2026 full year revenue guidance of $1.662 billion to $1.702 billion.
- 6
The company updated its 2026 adjusted earnings per share guidance from a range of $2.30 to $2.40 to a range of $2.40 to $2.50.
- 7
Adjusted EBITDA for the first quarter of 2026 was $76.2 million, or 19.4% of revenue, compared to $63.6 million, or 16.6% of revenue, in the prior year.
Management Comments
Mojdeh Poul
“Our first‑quarter results reflected solid product demand and the continued impact of our transformation efforts. We are seeing improving performance across the organization as operational rigor and improved execution take hold.” “During the quarter, we continued to drive improved supply reliability, supporting strong growth in Integra Skin and our return to market with PriMatrix® and Durepair®. We made meaningful progress at our state‑of‑the‑art Braintree manufacturing facility and remain on track to begin production of SurgiMend® by the end of June to support a fourth quarter launch. Building on these efforts, we are focused on maintaining disciplined execution and remain confident in our ability to deliver our full‑year commitments to our customers, patients, and shareholders."
Informational and educational content only. Not investment advice.